Enteric RET inhibition attenuates gastrointestinal secretion and motility via cholinergic signaling in rat colonic mucosal preparations
John P. Russell(GlaxoSmithKline (United Kingdom)), Beverley Greenwood–Van Meerveld(University of Oklahoma), Ehsan Mohammadi(University of Oklahoma Health Sciences Center), Allen Oliff(GlaxoSmithKline (United Kingdom)), Mui Cheung(GlaxoSmithKline (United Kingdom)), Anthony C. Johnson(University of Oklahoma Health Sciences Center), Rocco Latorre(University of Oklahoma Health Sciences Center), Melisa W-Y. Ho(GlaxoSmithKline (United Kingdom)), Hilary S. Eidam(GlaxoSmithKline (United Kingdom)), Michael P. DeMartino(GlaxoSmithKline (United Kingdom)), Casey O. Ligon(University of Oklahoma Health Sciences Center), Sanjay Kumar(GlaxoSmithKline (United States)), Bao Hoang(GlaxoSmithKline (United States)), David Krull(GlaxoSmithKline (United States))
Cited by 19
Related Papers
Intestinal barrier function in health and gastrointestinal disease
|Neurogastroenterology & Motility|2012|886
Stress and the Microbiota–Gut–Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome
|CNS Neuroscience & Therapeutics|2015|386
A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.
|PubMed|1995|385
Fundamentals of Neurogastroenterology: Basic Science
|Gastroenterology|2016|366